Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Tuesday 26 September, 2006

XTL Biopharm Ltd

Notice of AGM


         Annual General Meeting ("AGM") Notice Posted to Shareholders          

New York, New York, September 26, 2006 - XTL Biopharmaceuticals Ltd. (NASDAQ:
XTLB; LSE: XTL; TASE: XTL), a biotechnology company focused on the acquisition,
development and commercialization of pharmaceutical products for the treatment
of infectious diseases, particularly the treatment of hepatitis C, has posted
to shareholders a notice convening its AGM. The AGM will take place at the
Conference Room at the Company's Israeli offices at Building 3, Kiryat Weizmann
Science Park, Rehovot, Israel 76100, at 4:00 p.m., on October 25, 2006.

At the AGM it is proposed that:

  * the annual reports for the year ended 31 December 2005 be received;
   
  * Kesselman & Kesselman (PricewaterhouseCoopers) be reappointed as the
    Company's auditors; and
   
  * Messrs Michael Weiss, Ben Zion Weiner and William Kennedy be re-appointed
    as Directors of the Company.
   
Contacts:

XTL
Ron Bentsur, Chief Executive Officer Tel: +1 (212) 531-5960

ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL is engaged in the acquisition, development and commercialization of
therapeutics for the treatment of infectious diseases, with a focus on
hepatitis C. XTL is developing XTL-2125 - a small molecule, non-nucleoside
inhibitor of the hepatitis C virus polymerase - presently in Phase 1 clinical
trials in patients with chronic hepatitis C. XTL is also developing XTL-6865 -
a combination of two monoclonal antibodies against the hepatitis C virus -
presently in Phase 1 clinical trials in patients with chronic hepatitis C.
XTL's hepatitis C pipeline also includes several families of pre-clinical
hepatitis C small molecules. XTL is publicly traded on the Nasdaq, London, and
Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).


                                                                                                                                                                                                                            

a d v e r t i s e m e n t